Adults 18 to 65, any sex, with Multiple Sclerosis or Diet, Healthy. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Timed 25-foot Walk SpeedPrimary· Change from baseline to 8 weeks
Change in timed 25-foot walk test speed between baseline and 8 weeks. Speed calculated as ft per second, and change calculated as speed at baseline - speed at 8 weeks. Higher score indicates better outcome. There are no minimum or maximum values, as this is the measure of the time it takes a participant to walk 25 feet. Higher score indicates higher speed, which is preferable.
Group
Value
95% CI
Time Restricted Feeding
-.3
± 1.2
Short Form McGill Pain QuestionnaireSecondary· Change from baseline to 8 weeks
15-item questionnaire requiring respondent to rate types of pain as mild, moderate or severe. Scores range from 0-45, with higher pain intensity indicated by higher score. Change calculated as SFMPQ score at basline - SFMPQ score at 8 weeks.
Group
Value
95% CI
Time Restricted Feeding
-1.9
± 5.4
Modified Fatigue Impact ScaleSecondary· Change from baseline to 8 weeks
21-item questionnaire with possible score ranging from 0-84. Higher scores indicate higher impact of fatigue on a person's life. Change in MFIS was calculated as MFIS score at baseline - MFIS score at 8 weeks.
Group
Value
95% CI
Time Restricted Feeding
-1.3
± 14.3
Fatigue Severity ScaleSecondary· Change from baseline to 8 weeks
9-item questionnaire in respondents rate each statement from strongly disagree to strongly agree. Total scores range from 9- 63, with higher score indicating higher fatigue severity. Change in FSS calculated as FSS at baseline - FSS at 8 weeks.
Group
Value
95% CI
Time Restricted Feeding
2.3
± 16.7
Pittsburgh Sleep Quality IndexSecondary· Change from baseline to 8 weeks
19 self-rated items that produce 7 component scores and 1 global score. Only global scores were calculated for this study. Global scores can range from 0-21, with higher scores indicating poorer sleep quality. Change in PSQI calculated as PSQI at baseline - PSQI at 8 weeks.
Group
Value
95% CI
Time Restricted Feeding
.2
± 4.0
Percent Lean MassSecondary· Change from baseline to 8 weeks
Lean mass as a percent of total body mass, measured by dual energy x-ray absorptiometry (DXA)
Group
Value
95% CI
Time Restricted Feeding
0
± 1.0
9 Hole Peg Test SpeedSecondary· Change from baseline to 8 weeks
Higher score indicates better outcome. Speed on 9 hole peg test was measured as pegs per second, and change in speed was calculated as speed at baseline - speed at 8 weeks. There are no minimum or maximum values, as the measure is time that it takes a person to complete the test. Higher score indicates faster speed, which is preferable.
Group
Value
95% CI
Time Restricted Feeding
.02
± .03
Symbol Digit Modalities Test (SDMT)Secondary· Change from baseline to 8 weeks
The score is the number of symbols identified correctly in 90 seconds. Potential scores range from 0-110. Higher score indicate improved outcome. Change in score on the SDMT calculated as SDMT score at baseline- SDMT score at 8 weeks.
Group
Value
95% CI
Time Restricted Feeding
5.8
± 8.3
Percent Fat MassSecondary· Change from baseline to 8 weeks
Change in fat mass as percentage of total body mass, measured by DXA. Calculated as percent fat mass at baseline- percent fat mass at 8 weeks.
Group
Value
95% CI
Time Restricted Feeding
0
± 1.0
Sponsor's own description
The purpose of this pilot study is to determine the preliminary efficacy, safety, and acceptability of time restricted feeding (TRF) among a sample of 12 adults with Relapsing-Remitting Multiple Sclerosis (RRMS). The specific aims of this study are: 1: To determine preliminary efficacy of TRF for reducing symptom burden, improving inflammatory markers, and reducing cardiometabolic risk among adults with RRMS. 2: To determine the safety and participant acceptability of TRF. Participants will be asked to consume all food during an 8-hour window each day and not eat for the remaining 16 hours. All participants will follow this eating pattern for 8 weeks.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06480669 — Impact of Intermittent Fasting and Mediterranean Diet on the Physical Health of the Elderly
· NA
· completed
NCT05628727 — Intermittent Fasting Interventions on Brain Health in Women
· NA
· terminated
NCT04558827 — Low-Carb/Time-restricted Feeding Protocol in Insulin-Using Type 2 Diabetics
· NA
· completed
NCT04271748 — The Impact of Time Restricted Feeding in Crohn's Disease
· NA
· completed
NCT04463277 — A Comparison Between the Effects of Conventional Diets vs Intermittent Fasting Diabetic and Pre-diabetic Patients
· NA
· completed
Other recruiting trials for Multiple Sclerosis
Currently open trials in the same condition.
NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal
· NA
· recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga
· NA
· recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS
· recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity
· recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS
· NA
· recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis
· NA
· not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis
· NA
· withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis
· NA
· not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine
· Phase 2
· not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 27 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04389970.